PRVCF Tiny Float Could Rally On Breakthrough News
PreveCeutical Medical Inc. (PRVCF)
Germany: (18H.F)
Canada: (PREV.CN)
Alert Price: $0.0405
Float: 179.16M
Technical Analysis
We have just identified an exciting opportunity in the pharma sector.
Please turn your immediate attention to PreveCeutical Medical Inc. (PRVCF).
This cutting edge company develops innovative options for preventive and curative therapies utilizing organic and nature identical products.
PreveCeutical aims to be a leader in preventive health sciences.
PRVCF has one of the most impressive pipeline of treatments that we've ever seen.
The Company's current research and development programs include dual gene curative and preventive therapies for diabetes and obesity; the Cannabidiols Sol-gel Program aiming to provide relief across a range of indications from pain, inflammation, seizures, and neurological disorders; Nature Identical™ peptides for the treatment of various ailments; non-addictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury).
PRVCF has announced some major breakthroughs within the last few days that are sure to grab the attention of the Street.
In fact, just a few hours ago the Company announced another breakthrough in regards to their proprietary Sol-gels.
We have a feeling that PRVCF could be our next trade idea to more than double in price.
That being said, we ask that you add it to the top of your watchlist immediately, and be ready to trade at 9:30AM EST.
About PreveCeutical
PreveCeutical is a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature identical products.
PreveCeutical aims to be a leader in preventive health sciences. The Company's current research and development programs include dual gene curative and preventive therapies for diabetes and obesity; the Cannabidiols Sol-gel Program aiming to provide relief across a range of indications from pain, inflammation, seizures, and neurological disorders; Nature Identical™ peptides for the treatment of various ailments; non-addictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury).
PRVCF trades publicly in three countries, USA (OTCQB: PRVCF), Canada (CSE: PREV), and Germany (FSE: 18H).
PRVCF Has An Impressive Pipeline Of Cutting Edge Treatments
Cannabinoid Sol-Gel Delivery
NOSE-TO-BRAIN DELIVERY OF THERAPEUTIC CANNABINOIDS
Developing the first, sustained-release, cannabinoid-based nose-to-brain delivery system that will provide relief across a range of indications from pain, inflammation, seizures, and neurological disorders. Our proprietary nasal formulations will also be designed to be universally-patient friendly, meaning formulations that can be used in children and adults alike.
Sol-gels are taken via nasal administration and rapidly gel upon contact with mucosal tissue, which paves the way for direct nose-to-brain delivery. This effectively bypasses the stomach and intestines - eliminating first pass metabolism - and may dramatically improve bioavailability - even compared to nasal sprays and other newer delivery systems. Additionally, the gel stays in the nasal passages, slowly releasing the cannabinoid while keeping it active for up to seven days. The ease of application and its long-lasting effects may be attractive for patients when compared to other delivery systems.
BSV Peptide Program
TARGETING CANCER PROGRESSION
PreveCeutical, and research partner Uniquest, are currently screening peptides isolated from Caribbean Blue Scorpion venom across some of the most aggressive diseases where there exists unmet clinical need, such as cancer. There are numerous research papers in the public domain which show the anecdotal findings and efficacy of venom peptides taken through the proven route of administration on cancerous cells/tumours.
Recently the Company announced positive results from the preliminary screening of key peptides from its scorpion venom-derived peptide research and development program that is expected to enable PreveCeutical to generate Nature Identical™ peptide therapeutics intended for therapeutic applications. PreveCeutical’s initial focus is to understand the activities of such peptides in cell-based brain cancer models.
Through preliminary screening in a glioblastoma cell-based assay, PreveCeutical’s research team has successfully identified four lead peptides that inhibit the activity of a target protein implicit in the progression of certain aggressive brain cancers.
Further, the re-designed and synthesized peptides were found to be equally or more potent in the cell-based activity assay when compared to another scorpion peptide, Chlorotoxin. A series of more comprehensive screening assays are underway in the final stage of the Peptide Program, to allow the Company to develop a more detailed understanding of the activities of the peptides in progressively complex cell-based brain cancer models.
Non-Addictive Analgesic
ENGINEERING NON-ADDICTIVE ANALGESIC PEPTIDES FOR PAIN MANAGEMENT
PreveCeutical Medical Inc., and partner UniQuest Pty Ltd have signed a research and option agreement proposing to expand the use of their disulphide linker technology to develop non-addictive analgesics for moderate-to-severe pain.
This Research and Development program, led by Dr. Harry Parekh in-conjunction with his fellow collaborators at The University of Queensland’s School of Pharmacy, involves peptide library synthesis, pharmacological evaluation, alongside pharmacokinetic assessment and efficacy determinations in appropriate animal models of pain and inflammation, and may encompass either party’s intellectual property and product line and other pharmaceutical offerings that may fall within the peptide Research and Development program.
Dr. Parekh commented “This is a very exciting and important program as we focus on engineering a novel class of drugs derived from our very own endogenous pain pathways, for example when pain and inflammatory insults occur. Our preliminary work has highlighted that by using our proprietary linker technology we can enhance stability while maintaining, and in some cases enhancing the potency of lead bioactives. Having PreveCeutical on board will accelerate our current program, allowing us to rapidly expand and screen the bioactive library, taking the most promising candidates through to efficacy and pharmacokinetic evaluation.
Peptides are currently being used to target an array of disease indications including metabolic disorders, pain, cancers, cardiovascular and infectious diseases. The therapeutic peptide market is projected to undergo considerable expansion in the foreseeable future as technologies to enhance their stability and bioavailability emerge.
Dual Gene Therapy
TARGETING TYPE 2 DIABETES AND OBESITY
Over five years of multi-disciplinary research, Dr. Parekh’s team has collectively generated convincing results in models of this disease, using Smart siRNA and a Tissue Targeted Bio-responsive Carrier System. This program paves the way for preclinical evaluation of proprietary chemistry toward the single gene target implicated in type 2 diabetes and obesity, thereby reducing capacity to store fat, reversing obesity, fatty liver disease, and possibly curing the disease rather than just managing it.
PRVCF Drops Blockbuster News That Is Sure To Grab The Street's Attention
PreveCeutical Announces Sol-Gel Chemistry Fingerprinting SOPs
Just a few hours ago, the Company announced that it has successfully developed 'Standard Operating Procedures' ("SOPs") allowing for the chemical fingerprinting (profiling) of cannabinoids present in its extracts which can be used to formulate its proprietary Sol-gels for a variety of potential therapeutic applications.
This is an important development enabling a standardized preparation of cannabinoid extracts infused sol-gel formulations, ensuring robust cannabinoid chemistry profiling for different potential treatments to meet or exceed regulatory guidelines. This will enable PreveCeutical and potential partners to rapidly and consistently quality control the chemical composition of cannabinoids from any given cannabis/hemp strain, through adoption of its SOPs.
Mr. Stephen Van Deventer, Chairman and CEO, commented, "Having established this SOPs for cannabinoid chemical fingerprinting allows us to achieve precision, consistency and content uniformity in cannabinoid Sol-gel formulations. Furthermore, this SOPs will allow for prolonged controlled dosage release as required for specific treatments."
PRVCF Developing A Better Way For Cannabinoid Delivery
PreveCeutical Announces Successful Completion of its Sol-gel Program
Earlier this month, the Company announced the successful completion of its Cannabinoid Sol-Gel Delivery Program (the "Sol-gel Program").
The Sol-gel Program developed and evaluated translatable formulations for the central nervous system (CNS) delivery of cannabinoid extracts ("CBDs"). Soluble gels (solgels) present an ideal platform for achieving this aim, being in-solution upon administration, and rapidly gelling upon contact with mucosal tissue, paving the way for safer, reliable drug delivery for agents, such as CBDs that are rapidly metabolized, or that would benefit from direct nose-to-brain CNS delivery to provide clinical benefit.
Cannabis is currently generating considerable interest in medical research to treat illnesses or symptoms across epilepsy, neuropathic pain, multiple sclerosis, palliative care associated with AIDS, cachexia and appetite enhancement, cancer and chemotherapy-induced nausea and vomiting, Crohn's disease and glaucoma.
The Company is planning on developing lead cannabinoid formulations that may provide therapies aiming to address the various illnesses with plans to commercialize after clinical trials have been conducted.
The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain any of the ailments listed above, at this time.
The Company will provide further upon when the final Sol-Gel Program report is received from UniQuest Pty Limited. This will allow PreveCeutical to file patents to secure our intellectual property derived from this program.
PreveCeutical's President and Chief Science Officer, Dr. Mak Jawadekar, stated, "Completion of the CBD Sol-Gel Program is a very significant milestone achievement for PreveCeutical. We are very excited about the therapeutic opportunities that will be derived from the program and look forward to progressing them through proof of concept studies".
PRVCF Changing The Game When It Comes To Pain Management
PreveCeutical Confirms its First Peptide with Promising Pre-Clinical Efficacy as a Non-Addictive Painkiller
In April the Company announced an update to its Non-Addictive Analgesic (dynorphin pain peptide) Program.
Following the identification and shortlisting of a panel of peptides showing promising cell-based activity and extended stability in two distinct types of biological media, the program has identified its first peptide with clear "in vivo" activity in a rat model of inflammatory pain. This pre-clinical peptide has demonstrated effectiveness in alleviating moderate inflammatory pain after administration of a single dose. It is planned to test other shortlisted peptides from the panel for their analgesic activity in the in vivo rat model.
This outcome highlights the potential of appropriately designed, opioid-receptor selective peptides in alleviating pain.
PreveCeutical's President and Chief Science Officer, Dr. Mak Jawadekar, stated, "This novel peptide has the potential for further development as a non-addictive analgesic drug candidate, based on the 'pre-clinical' animal studies that have been conducted so far."
Market Outlook
The global cannabis - Cannabinoid market reportedly reached $13.4 Billion in 2018, and it is expected to reach even greater heights in the near future… in fact the market is expected to grow at a CAGR of 22.9% during 2019-2024, reaching a value of US$ 44.4 Billion by 2024, according to a research report by IMARC Group. It "what's old is new again" given the fact that historically, cannabis has been used medicinally for years in ancient Indian, Chinese, Egyptian and Islamic cultures. Nowadays, cannabis finds application in the treatment of a wide range of diseases and symptoms including cancer, chronic pain, depression, arthritis, diabetes, glaucoma, migraines, epilepsy, MS, AIDS, ALS, Alzheimer's, PTSD, Parkinson's, Tourette's, etc. Owing to its therapeutic benefits, cannabis has been approved for medical use in numerous countries, with varying degrees of legal restriction.
Global Pain Management Drugs Market to Reach $77.13 Billion by 2023 at 4% CAGR, Says Allied Market Research
The global pain management drugs market was pegged at $61.05 billion in 2017 and is projected to garner $77.13 billion by 2023, registering a CAGR of 4% from 2017 to 2023.
The global market for diabetes care products including drugs and devices expected to exceed $111.2 billion by 2027, expanding at a CAGR of 3.9% over the forecast period, driven by increasing prevalence of obesity, unhealthy lifestyles and diabetic population worldwide.
Technical Analysis
PRVCF Could See A Major Reversal Here
We've done our very own technical analysis, and see the potential for an over +40% move from here.
Bullish Indicators:
7-12-20 MA's In Strong Uptrend
Bullish Golden Cross 50MA Crosses Over The 200MA
Accumulation
Bullish MACD And Histogram
Volume Spike As CMF Crosses Zero Line Bullishly
With its razor thin float, PRVCF is no stranger to big time single-session moves.
One just has to examine its price history, to see that this ticker can run like the win.
We've noticed several double-digit swings within the past few trading sessions.
Those on the hunt for big moves need not look any further.
The Bottom Line
PRVCF has one of the most impressive pipeline of treatments that we've ever seen.
PRVCF has announced some major breakthroughs within the last few days that are sure to grab the attention of the Street.
The Company is in the midst of a major growth period, and is operating in an several industries that are set to boom.
As we mentioned above, this could easily be our next trade idea to double in price, so we suggest you start your research now, and add it to the top of your watchlist immediately.
By Viewing this Content, you Agree that you Have Read and are in Full Understanding of both our Disclaimer & Privacy Policy(*Remember to use a Stop-Loss Order to protect your gains, as well as limit possible losses.) Best regards
Germany: (18H.F)
Canada: (PREV.CN)
Alert Price: $0.0405
Float: 179.16M
Technical Analysis
We have just identified an exciting opportunity in the pharma sector.
Please turn your immediate attention to PreveCeutical Medical Inc. (PRVCF).
This cutting edge company develops innovative options for preventive and curative therapies utilizing organic and nature identical products.
PreveCeutical aims to be a leader in preventive health sciences.
PRVCF has one of the most impressive pipeline of treatments that we've ever seen.
The Company's current research and development programs include dual gene curative and preventive therapies for diabetes and obesity; the Cannabidiols Sol-gel Program aiming to provide relief across a range of indications from pain, inflammation, seizures, and neurological disorders; Nature Identical™ peptides for the treatment of various ailments; non-addictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury).
PRVCF has announced some major breakthroughs within the last few days that are sure to grab the attention of the Street.
In fact, just a few hours ago the Company announced another breakthrough in regards to their proprietary Sol-gels.
We have a feeling that PRVCF could be our next trade idea to more than double in price.
That being said, we ask that you add it to the top of your watchlist immediately, and be ready to trade at 9:30AM EST.
About PreveCeutical
PreveCeutical is a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature identical products.
PreveCeutical aims to be a leader in preventive health sciences. The Company's current research and development programs include dual gene curative and preventive therapies for diabetes and obesity; the Cannabidiols Sol-gel Program aiming to provide relief across a range of indications from pain, inflammation, seizures, and neurological disorders; Nature Identical™ peptides for the treatment of various ailments; non-addictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury).
PRVCF trades publicly in three countries, USA (OTCQB: PRVCF), Canada (CSE: PREV), and Germany (FSE: 18H).
PRVCF Has An Impressive Pipeline Of Cutting Edge Treatments
Cannabinoid Sol-Gel Delivery
NOSE-TO-BRAIN DELIVERY OF THERAPEUTIC CANNABINOIDS
Developing the first, sustained-release, cannabinoid-based nose-to-brain delivery system that will provide relief across a range of indications from pain, inflammation, seizures, and neurological disorders. Our proprietary nasal formulations will also be designed to be universally-patient friendly, meaning formulations that can be used in children and adults alike.
Sol-gels are taken via nasal administration and rapidly gel upon contact with mucosal tissue, which paves the way for direct nose-to-brain delivery. This effectively bypasses the stomach and intestines - eliminating first pass metabolism - and may dramatically improve bioavailability - even compared to nasal sprays and other newer delivery systems. Additionally, the gel stays in the nasal passages, slowly releasing the cannabinoid while keeping it active for up to seven days. The ease of application and its long-lasting effects may be attractive for patients when compared to other delivery systems.
BSV Peptide Program
TARGETING CANCER PROGRESSION
PreveCeutical, and research partner Uniquest, are currently screening peptides isolated from Caribbean Blue Scorpion venom across some of the most aggressive diseases where there exists unmet clinical need, such as cancer. There are numerous research papers in the public domain which show the anecdotal findings and efficacy of venom peptides taken through the proven route of administration on cancerous cells/tumours.
Recently the Company announced positive results from the preliminary screening of key peptides from its scorpion venom-derived peptide research and development program that is expected to enable PreveCeutical to generate Nature Identical™ peptide therapeutics intended for therapeutic applications. PreveCeutical’s initial focus is to understand the activities of such peptides in cell-based brain cancer models.
Through preliminary screening in a glioblastoma cell-based assay, PreveCeutical’s research team has successfully identified four lead peptides that inhibit the activity of a target protein implicit in the progression of certain aggressive brain cancers.
Further, the re-designed and synthesized peptides were found to be equally or more potent in the cell-based activity assay when compared to another scorpion peptide, Chlorotoxin. A series of more comprehensive screening assays are underway in the final stage of the Peptide Program, to allow the Company to develop a more detailed understanding of the activities of the peptides in progressively complex cell-based brain cancer models.
Non-Addictive Analgesic
ENGINEERING NON-ADDICTIVE ANALGESIC PEPTIDES FOR PAIN MANAGEMENT
PreveCeutical Medical Inc., and partner UniQuest Pty Ltd have signed a research and option agreement proposing to expand the use of their disulphide linker technology to develop non-addictive analgesics for moderate-to-severe pain.
This Research and Development program, led by Dr. Harry Parekh in-conjunction with his fellow collaborators at The University of Queensland’s School of Pharmacy, involves peptide library synthesis, pharmacological evaluation, alongside pharmacokinetic assessment and efficacy determinations in appropriate animal models of pain and inflammation, and may encompass either party’s intellectual property and product line and other pharmaceutical offerings that may fall within the peptide Research and Development program.
Dr. Parekh commented “This is a very exciting and important program as we focus on engineering a novel class of drugs derived from our very own endogenous pain pathways, for example when pain and inflammatory insults occur. Our preliminary work has highlighted that by using our proprietary linker technology we can enhance stability while maintaining, and in some cases enhancing the potency of lead bioactives. Having PreveCeutical on board will accelerate our current program, allowing us to rapidly expand and screen the bioactive library, taking the most promising candidates through to efficacy and pharmacokinetic evaluation.
Peptides are currently being used to target an array of disease indications including metabolic disorders, pain, cancers, cardiovascular and infectious diseases. The therapeutic peptide market is projected to undergo considerable expansion in the foreseeable future as technologies to enhance their stability and bioavailability emerge.
Dual Gene Therapy
TARGETING TYPE 2 DIABETES AND OBESITY
Over five years of multi-disciplinary research, Dr. Parekh’s team has collectively generated convincing results in models of this disease, using Smart siRNA and a Tissue Targeted Bio-responsive Carrier System. This program paves the way for preclinical evaluation of proprietary chemistry toward the single gene target implicated in type 2 diabetes and obesity, thereby reducing capacity to store fat, reversing obesity, fatty liver disease, and possibly curing the disease rather than just managing it.
PRVCF Drops Blockbuster News That Is Sure To Grab The Street's Attention
PreveCeutical Announces Sol-Gel Chemistry Fingerprinting SOPs
Just a few hours ago, the Company announced that it has successfully developed 'Standard Operating Procedures' ("SOPs") allowing for the chemical fingerprinting (profiling) of cannabinoids present in its extracts which can be used to formulate its proprietary Sol-gels for a variety of potential therapeutic applications.
This is an important development enabling a standardized preparation of cannabinoid extracts infused sol-gel formulations, ensuring robust cannabinoid chemistry profiling for different potential treatments to meet or exceed regulatory guidelines. This will enable PreveCeutical and potential partners to rapidly and consistently quality control the chemical composition of cannabinoids from any given cannabis/hemp strain, through adoption of its SOPs.
Mr. Stephen Van Deventer, Chairman and CEO, commented, "Having established this SOPs for cannabinoid chemical fingerprinting allows us to achieve precision, consistency and content uniformity in cannabinoid Sol-gel formulations. Furthermore, this SOPs will allow for prolonged controlled dosage release as required for specific treatments."
PRVCF Developing A Better Way For Cannabinoid Delivery
PreveCeutical Announces Successful Completion of its Sol-gel Program
Earlier this month, the Company announced the successful completion of its Cannabinoid Sol-Gel Delivery Program (the "Sol-gel Program").
The Sol-gel Program developed and evaluated translatable formulations for the central nervous system (CNS) delivery of cannabinoid extracts ("CBDs"). Soluble gels (solgels) present an ideal platform for achieving this aim, being in-solution upon administration, and rapidly gelling upon contact with mucosal tissue, paving the way for safer, reliable drug delivery for agents, such as CBDs that are rapidly metabolized, or that would benefit from direct nose-to-brain CNS delivery to provide clinical benefit.
Cannabis is currently generating considerable interest in medical research to treat illnesses or symptoms across epilepsy, neuropathic pain, multiple sclerosis, palliative care associated with AIDS, cachexia and appetite enhancement, cancer and chemotherapy-induced nausea and vomiting, Crohn's disease and glaucoma.
The Company is planning on developing lead cannabinoid formulations that may provide therapies aiming to address the various illnesses with plans to commercialize after clinical trials have been conducted.
The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain any of the ailments listed above, at this time.
The Company will provide further upon when the final Sol-Gel Program report is received from UniQuest Pty Limited. This will allow PreveCeutical to file patents to secure our intellectual property derived from this program.
PreveCeutical's President and Chief Science Officer, Dr. Mak Jawadekar, stated, "Completion of the CBD Sol-Gel Program is a very significant milestone achievement for PreveCeutical. We are very excited about the therapeutic opportunities that will be derived from the program and look forward to progressing them through proof of concept studies".
PRVCF Changing The Game When It Comes To Pain Management
PreveCeutical Confirms its First Peptide with Promising Pre-Clinical Efficacy as a Non-Addictive Painkiller
In April the Company announced an update to its Non-Addictive Analgesic (dynorphin pain peptide) Program.
Following the identification and shortlisting of a panel of peptides showing promising cell-based activity and extended stability in two distinct types of biological media, the program has identified its first peptide with clear "in vivo" activity in a rat model of inflammatory pain. This pre-clinical peptide has demonstrated effectiveness in alleviating moderate inflammatory pain after administration of a single dose. It is planned to test other shortlisted peptides from the panel for their analgesic activity in the in vivo rat model.
This outcome highlights the potential of appropriately designed, opioid-receptor selective peptides in alleviating pain.
PreveCeutical's President and Chief Science Officer, Dr. Mak Jawadekar, stated, "This novel peptide has the potential for further development as a non-addictive analgesic drug candidate, based on the 'pre-clinical' animal studies that have been conducted so far."
Market Outlook
The global cannabis - Cannabinoid market reportedly reached $13.4 Billion in 2018, and it is expected to reach even greater heights in the near future… in fact the market is expected to grow at a CAGR of 22.9% during 2019-2024, reaching a value of US$ 44.4 Billion by 2024, according to a research report by IMARC Group. It "what's old is new again" given the fact that historically, cannabis has been used medicinally for years in ancient Indian, Chinese, Egyptian and Islamic cultures. Nowadays, cannabis finds application in the treatment of a wide range of diseases and symptoms including cancer, chronic pain, depression, arthritis, diabetes, glaucoma, migraines, epilepsy, MS, AIDS, ALS, Alzheimer's, PTSD, Parkinson's, Tourette's, etc. Owing to its therapeutic benefits, cannabis has been approved for medical use in numerous countries, with varying degrees of legal restriction.
Global Pain Management Drugs Market to Reach $77.13 Billion by 2023 at 4% CAGR, Says Allied Market Research
The global pain management drugs market was pegged at $61.05 billion in 2017 and is projected to garner $77.13 billion by 2023, registering a CAGR of 4% from 2017 to 2023.
The global market for diabetes care products including drugs and devices expected to exceed $111.2 billion by 2027, expanding at a CAGR of 3.9% over the forecast period, driven by increasing prevalence of obesity, unhealthy lifestyles and diabetic population worldwide.
Technical Analysis
PRVCF Could See A Major Reversal Here
We've done our very own technical analysis, and see the potential for an over +40% move from here.
Bullish Indicators:
7-12-20 MA's In Strong Uptrend
Bullish Golden Cross 50MA Crosses Over The 200MA
Accumulation
Bullish MACD And Histogram
Volume Spike As CMF Crosses Zero Line Bullishly
With its razor thin float, PRVCF is no stranger to big time single-session moves.
One just has to examine its price history, to see that this ticker can run like the win.
We've noticed several double-digit swings within the past few trading sessions.
Those on the hunt for big moves need not look any further.
The Bottom Line
PRVCF has one of the most impressive pipeline of treatments that we've ever seen.
PRVCF has announced some major breakthroughs within the last few days that are sure to grab the attention of the Street.
The Company is in the midst of a major growth period, and is operating in an several industries that are set to boom.
As we mentioned above, this could easily be our next trade idea to double in price, so we suggest you start your research now, and add it to the top of your watchlist immediately.
By Viewing this Content, you Agree that you Have Read and are in Full Understanding of both our Disclaimer & Privacy Policy(*Remember to use a Stop-Loss Order to protect your gains, as well as limit possible losses.) Best regards